Rheumatic Myocarditis Treatment Market size was valued at USD 1.05 Billion in 2023 and is anticipated to reach USD 1.95 Billion by the end of 2036, registering around 4.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of rheumatic myocarditis treatment is assessed at USD 1.1 Billion. The major factor attributed to market growth is the rising incidence of rheumatic heart disease among the global population and the increasing prevalence of rheumatic fever which is generating the need for rheumatic myocarditis treatment during the forecast period. According to a recently published report in 2021, it is estimated that around 34 million people around the world have rheumatic heart disease. Moreover, it is being calculated that 300,000 to 500,000 new cases of rheumatic fever are diagnosed every year worldwide.
In addition to the aforementioned factors, the rapid advancement in drugs and biotechnology is estimated to bring in lucrative growth opportunities for the expansion of the global rheumatic myocarditis treatment. Apart from this, the escalation in cases of rheumatic fever, and strep throat along with the growing prevalence of inflammatory diseases around the world is anticipated to create a positive outlook for market growth during the forecast period. Furthermore, another factor that is estimated to drive the rising focus of the governments of different nations to enhance healthcare facilities and medical offerings. Also, the rising cases of chronic diseases and cardiovascular disorders which lead to rheumatic myocarditis are forecasted to generate a high demand for rheumatic myocarditis treatment which is estimated to subsequently increase the market size in the upcoming years.
Growth Drivers
Rapid Rise in the Number of Cases of Rheumatic Fever – In the recent period, there has been a global burden on the economy owing to the increasing rheumatic fever around the world which is developed as a result of strep throat. Treating such autoimmune diseases is estimated to increase the utilization rate of rheumatic myocarditis treatment, especially in low and middle-income countries. The report published by the Centers for Disease Control and Prevention (CDC) estimated that around 470,000 new cases of acute rheumatic fever are diagnosed every year around the globe.
Rising Incidences of Cardiovascular Diseases Among the Global Population – More and more people have been diagnosed with cardiovascular diseases in the past years as a result of shifting towards a sedentary lifestyle and consumption of unhealthy food items. The rising cases of cardiovascular diseases could weaken the heart and deteriorate the functioning of heart values which could lead to rheumatic myocarditis. Thus, the escalation in cardiovascular diseases is estimated to bring favorable opportunities for market expansion in the forecast period. The World Health Organization (WHO) stated that cardiovascular diseases are considered to be a major cause of deaths occurring at the global level, taking almost 17.9 million lives each year.
Lack of Basic Sanitation Facilities – Even though the economies are growing, a major portion of people are living without basic sanitation facilities. Living under unhygienic conditions is estimated to increase the occurrence of rheumatic fever which ultimately leads to rheumatic heart disease. Therefore, the absence of fundamental facilities for hygiene is estimated to generate the need for rheumatic myocarditis treatment during the forecast period to treat patients. The Centers for Disease Control and Prevention (CDC) stated that around 3.6 billion people around the world lack access to safely managed sanitation in their homes and around 2 billion people worldwide lack basic safe drinking water services.
Growing Percentage of Elderly People in the World – Old people have weakened bodies and deteriorating body organs which makes them prone to rheumatic myocarditis. Thus, with the burgeoning population, it is estimated that the demand for rheumatic myocarditis treatment is expected to grow during the forecast period. The data released by the Department of Economic and Social Affairs, United Nations revealed that in 2019, approximately 703 million people of age 65 and above were present. This figure is estimated to double by 2050 to reach almost 2.1 billion worldwide.
High Amount of Investment in Developing the Healthcare Sector – Key players operating in the market along with the governments of different countries are focusing on developing novel medicinal products and advanced medical items for rheumatic myocarditis treatment. As a result, a high amount is being invested in the healthcare sector to aid research and development activities. For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD 245 billion in 2020 from previous years.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.9% |
|
Base Year Market Size (2023) |
USD 1.05 Billion |
|
Forecast Year Market Size (2036) |
USD 1.95 Billion |
|
Regional Scope |
|
Diagnosis (Blood Tests, Echocardiogram, Electrocardiogram)
The global rheumatic myocarditis treatment market is segmented and analyzed for demand and supply by diagnosis into blood tests, echocardiograms, electrocardiograms, and others. Out of these, the electrocardiograms segment is estimated to gain the largest market share of about 41% in the year 2036. The major factor attributed to segment growth is the growing advantages of electrocardiograms and the usage of electrocardiograms for the detection of fatal diseases such as rheumatic myocarditis. As per a report published in the National Library of Medicine in 2022, it has been calculated that almost 300 million electrocardiograms are conducted every year across the world. Also, the availability of advanced medical products for the proper functioning of electrocardiograms is anticipated to create a positive outlook for significant revenue generation and segment growth.
End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare)
The global rheumatic myocarditis treatment market is also segmented and analyzed for demand and supply by end-user into hospitals, ambulatory surgical centers, specialty clinics, homecare, and others. Amongst these segments, the hospital segment is expected to garner a significant share of around 35% in the year 2036 with a significant CAGR value. The major factor that is attributed to segment growth is the increasing development of hospital infrastructure across the world and the availability of hospitals in every region that helps in aiding the treatment of rheumatic myocarditis in hospital settings. For instance, there were over 8,000 hospitals in Japan as of 2020. Korea, by contrast, had about 4,000 hospitals. In addition, there were more than 6000 hospitals in the United States. Also, the rising preference of the global population to get treated in hospitals for rheumatic myocarditis owing to the availability of specialized doctors, enhanced infrastructure, and technologically-advanced medical products for treatment procedures.
Our in-depth analysis of the global market includes the following segments:
|
By Age Group |
|
|
By Diagnosis |
|
|
Treatment |
|
|
By End User |
|
North American Market Forecast
The North American rheumatic myocarditis treatment market, amongst the market in all the other regions, is projected to hold the largest market share of about 35% by the end of 2036. The growth of the market can be attributed majorly to the increasing frequency of rheumatic fever and subsequently rheumatic myocarditis amongst several people, backed by rising awareness about the disease among people and high healthcare expenditure for treatment procedures. For instance, the Centers for Medicare and Medicaid Services stated that the National Health Expenditure (NHE) of Americans grew almost 2.7% to reach USD 4.3 trillion which is also equivalent to USD 12,914 per person in 2021. It has also been calculated that national healthcare expenditure accounted for approximately 18.3% of the nation’s total Gross Domestic Product (GDP). Further, the presence of a strong healthcare network in the region, along with the availability of supportive advanced therapy medicinal products to develop efficient treatment options, are also anticipated to contribute to market growth in the region. In addition, the high expenditure for expanding the healthcare industry and rising initiatives by the government to increase the awareness level about the disease in the region are also anticipated to spur market growth during the forecast period.
APAC Market Statistics
The Asia Pacific rheumatic myocarditis treatment market, amongst the market in all the other regions, is projected to hold the second largest share of about 24% during the forecast period. The major factor for market growth is the rising pool of patients diagnosed with chronic diseases which leads to rheumatic fever and rheumatic myocarditis. Also, the presence of biobanking and e-prescribing in the region is estimated to bring favorable options for the adoption of rheumatic myocarditis treatment among the people living in the region. Furthermore, the presence of major key players in the region and their increased active participation in developing novel techniques for rheumatic myocarditis treatment is also estimated to bring lucrative growth opportunities for market growth during the forecast period.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The rising initiatives by the major key players and the European government to increase the awareness level of the disease and its treatment coupled with the rising shift of people towards health and fitness are considered to be major factors for market expansion in the region in the upcoming years.
Siemens Healthcare GmbH has launched the technologically-advanced multidisciplinary angiography system ARTIS icono. With its development, the company is expected to cater to different needs of cardiovascular interventions, interventional radiology, neuroradiology, and vascular interventions.
Pfizer Inc. has finally acquired Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company that is dedicated to the discovery, development, and delivery of life-changing treatments for patients diagnosed with sickle cell disease (SCD). The acquisition is anticipated to broaden the offerings provided by the company.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?